News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

ProMetic Life Sciences Inc. (PFSCF.PK) Announces Signature of Definitive License Agreement With Kedrion S.p.A. for Two Hyperimmune Products



2/26/2008 9:36:25 AM

MONTREAL, QUEBEC--(Marketwire - February 26, 2008) - ProMetic Life Sciences Inc. ("ProMetic") (TSX: PLI) announced today that it has signed the definitive agreement for development of two hyperimmunes with Kedrion S.p.A. ("Kedrion").

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES